© 2021 All Rights reserved WUSF
News, Jazz, NPR
Play Live Radio
Next Up:
0:00
0:00
Available On Air Stations

Johnson & Johnson's COVID Vaccine Is Effective Against The Delta Variant, Studies Find

The Johnson & Johnson COVID-19 vaccine continued to be effective over the eight months it was studied in recipients, the company said.
The Johnson & Johnson COVID-19 vaccine continued to be effective over the eight months it was studied in recipients, the company said.

Johnson & Johnson's COVID-19 vaccine offers strong protection against the delta variant of the coronavirus, the company said Thursday. And the protection appears to last at least eight months.

The results follow similar announcements about the Pfizer and Moderna vaccines in the fight against the fast-spreading delta strain.

In one small laboratory study, researchers observed what happened to the blood of eight vaccinated individuals when it was exposed to the delta variant. And they found that antibodies and immune system cells in the blood were highly effective at neutralizing the virus.

A second study involving 20 patients at Beth Israel Deaconess Medical Center in Boston showed similar results.

Johnson & Johnson also noted the vaccine continued to be effective over the eight months it was studied in recipients. Dr. Mathai Mammen, the company's global head of research and development, said the vaccine elicits a "strong neutralizing antibody response that does not wane; rather, we observe an improvement over time."

Both studies have been submitted but not yet published in a peer-reviewed publication.

Copyright 2021 NPR. To see more, visit https://www.npr.org.

WUSF 89.7 depends on donors for the funding it takes to provide you the most trusted source of news and information here in town, across our state, and around the world. Support WUSF now by giving monthly, or make a one-time donation online.